P&G buys Thorne for $3.8 billion, doubling down on premium wellness

Procter & Gamble has agreed to acquire Thorne, the supplements and personalised health company, for $3.8 billion, in a move that extends the consumer giant's personal health care division into premium wellness. Thorne has built its reputation on clinically informed supplements, at-home testing and a direct relationship with health-conscious, higher-spending consumers, a positioning that differs sharply from the mass-market drugstore model P&G has traditionally relied on for its health brands.

The acquisition fits a broader pattern of large consumer groups buying their way into wellness rather than building it organically, chasing a category that has proven resilient even as discretionary spending elsewhere softens. For P&G, Thorne offers a premium, science-led brand and a subscription-style customer base that could support higher margins than its legacy portfolio. It also gives the group a foothold in a space increasingly contested by beauty and pharma companies alike, as the line between skincare, supplements and healthcare continues to blur.

The deal is notable for the luxury and premium sector because it confirms wellness as one of the few growth pockets attracting serious capital right now, even as apparel, accessories and some beauty categories slow. Watch for how P&G integrates Thorne without diluting its clinical credibility, and whether the price paid signals more consolidation to come as strategics compete with private equity for scarce premium wellness assets.

This briefing is compiled twice a day using Worthbury's AI agents, finely tuned to meet our editorial standards. While we test and review their work, mistakes can sometimes happen. See exactly how it works.